[1]
Ossenkoppele, G.J.; Janssen, J.J.; van de Loosdrecht, A.A. Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematologica, 2016, 101(1), 20-25.
[2]
Leufven, E.; Bruserud, Ø. Immunosuppression and immunotargeted therapy in acute myeloid leukemia – the potential use of checkpoint inhibitors in combination with other treatments. Curr. Med. Chem., 2019, 26(28), 5244-5261.
[3]
Azrakhsh, N.A.; Mensah-Glanowska, P.; Sand, K.; Kittang, A.O. Targeting immune signaling pathways in clonal hematopoiesis. Curr. Med. Chem., 2019, 26(28), 5262-5277.
[4]
Singh, A.; Myklebust, N.N.; Furevik, S.M.V.; Haugse, R.; Herfindal, L. Immunoliposomes in acute myeloid leukaemia therapy. An overview of possible targets and obstacles. Curr. Med. Chem., 2019, 26(28), 5278-5292.
[5]
Selheim, F.; Aasebø, E.; Catalina Ribas, C.; Aragay, A.M. An overview on G protein-coupled receptor-induced signal transduction in Acute Myeloid Leukemia. Curr. Med. Chem., 2019, 26(28), 5293-5316.
[6]
Hernandez-Valladares, M.; Wangen, R.; Berven, F.S.; Guldbrandsen, A. Protein Post-Translational Modification Crosstalk in Acute Myeloid Leukemia Calls for Action. Curr. Med. Chem., 2019, 26(28), 5317-5337.
